Display options
Cite
Naik R, Khan MA. Doceaqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: A case report. Mol Clin Oncol. 2017;6(3):341-343doi: 10.3892/mco.2017.1147.
Naik, R., & Khan, M. A. (2017). Doceaqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: A case report. Molecular and clinical oncology, 6(3), 341-343. https://doi.org/10.3892/mco.2017.1147
Naik, Radheshyam, and Khan, Mujtaba A. "Doceaqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: A case report." Molecular and clinical oncology vol. 6,3 (2017): 341-343. doi: https://doi.org/10.3892/mco.2017.1147
Naik R, Khan MA. Doceaqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: A case report. Mol Clin Oncol. 2017 Mar;6(3):341-343. doi: 10.3892/mco.2017.1147. Epub 2017 Feb 02. PMID: 28451410; PMCID: PMC5403271.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2017 Mar;6(3):341-343. doi: 10.3892/mco.2017.1147. Epub 2017 Feb 02.

Doceaqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: A case report.

Molecular and clinical oncology

Radheshyam Naik, Mujtaba A Khan

Affiliations

  1. Department of Medical Oncology, HCG Hospital, Bangalore, Karnataka 560027, India.
  2. Department of Medical Affairs, Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat 382210, India.

PMID: 28451410 PMCID: PMC5403271 DOI: 10.3892/mco.2017.1147

Abstract

Docetaxel has been widely used in the treatment of several cancers, including adenocarcinoma of the prostate gland. As docetaxel is insoluble in water, it must be administered with polysorbate 80 and ethanol, which are known to cause hypersensitivity reactions. Premedication with corticosteroids and antihistamines is advocated prior to docetaxel administration; however, toxicities, occasionally fatal, have been reported, even with corticosteroid premedication. We herein report the case of a patient with adenocarcinoma of the prostate, with bone metastasis and an Eastern Cooperative Oncology Group performance status of <2, who developed an allergic reaction to conventional docetaxel (Taxotere), despite being premedicated with corticosteroids and antihistamines. The patient was managed with corticosteroids and antihistamines, and was later started on Doceaqualip, a nanosomal docetaxel lipid suspension. Doceaqualip was well-tolerated by the patient and 5 cycles were subsequently administered, without any adverse reactions. Adenocarcinoma also regressed, as evidenced by positron emission tomography/computed tomography.

Keywords: Doceaqualip; adenocarcinoma; docetaxel; nanosomal; prostate cancer

References

  1. Cancers (Basel). 2011 Nov 08;3(4):4127-38 - PubMed
  2. Agents Actions. 1985 Sep;16(6):470-7 - PubMed
  3. J Clin Oncol. 1995 Dec;13(12):2886-94 - PubMed
  4. Clin Breast Cancer. 2014 Jun;14(3):177-81 - PubMed
  5. Ann Oncol. 2006 May;17 (5):735-49 - PubMed
  6. Int J Pharm. 2010 Sep 15;397(1-2):103-8 - PubMed
  7. J Clin Oncol. 2009 Sep 20;27(27):4522-9 - PubMed
  8. J Clin Oncol. 2012 May 1;30(13):1534-40 - PubMed
  9. Int J Nanomedicine. 2008;3(2):133-49 - PubMed
  10. Clin Pharmacol Ther. 2003 Oct;74(4):364-71 - PubMed
  11. Semin Oncol. 2002 Jun;29(3 Suppl 12):1-3 - PubMed
  12. Int J Pharm. 2004 Oct 13;284(1-2):109-22 - PubMed
  13. ACS Nano. 2009 Jan 27;3(1):16-20 - PubMed
  14. Cancer Treat Rev. 1995 Sep;21(5):463-78 - PubMed
  15. Int Immunopharmacol. 2010 Mar;10(3):325-30 - PubMed
  16. Eur J Pharm Biopharm. 2008 Jun;69(2):527-34 - PubMed
  17. Support Care Cancer. 2015 Jul;23(7):1969-77 - PubMed
  18. Clin Pharmacokinet. 2003;42(7):665-85 - PubMed
  19. J Pharm Sci. 2009 Aug;98(8):2718-30 - PubMed
  20. Biomaterials. 2009 Jul;30(19):3297-306 - PubMed
  21. J Control Release. 2008 May 22;128(1):23-31 - PubMed
  22. Bioorg Med Chem. 2007 Sep 15;15(18):6323-30 - PubMed
  23. Clin J Oncol Nurs. 2013 Feb;17 Suppl:15-21 - PubMed

Publication Types